Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestMortgage LoansNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - DoubtfulReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

WORK Medical Technology (WOK) Cash & Equivalents (2023 - 2025)

WORK Medical Technology (WOK) posted Cash & Equivalents of $4.1 million for Q3 2025, up 104.86% on a QoQ basis from $2.0 million in Q1 2025, and down 37.65% year-over-year from $6.6 million in Q3 2024.

WORK Medical Technology (WOK) has 3 years of Cash & Equivalents data on file, last reported at $4.1 million in Q3 2025.

  • In Q3 2025, Cash & Equivalents fell 37.65% year-over-year to $4.1 million; the TTM figure through Sep 2025 stood at $4.1 million (down 37.65% YoY), while the FY2025 annual figure was $4.1 million, down 37.65% from the prior year.
  • Cash & Equivalents improved to $4.1 million in Q3 2025, from $2.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $6.6 million in Q3 2024 and bottomed at $1.6 million in Q3 2023.
  • A 3-year average of $3.6 million and a median of $3.0 million in 2025 frame the typical range for Cash & Equivalents.
  • Annual changes were most pronounced in 2024 — Cash & Equivalents surged 310.85% — and 2025, when it slumped 37.65%.
  • Year by year, Cash & Equivalents stood at $1.6 million in 2023, then surged by 310.85% to $6.6 million in 2024, then sank by 37.65% to $4.1 million in 2025.
  • The last three Cash & Equivalents figures came in at $4.1 million (Q3 2025), $2.0 million (Q1 2025), and $6.6 million (Q3 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 6.80 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 2.88 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 1.15 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 1.45 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 2.45 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 3.03 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 1.12 Bn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 2.29 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 439.60 Mn
10 WORK Medical Technology - - - 4.09 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2025 4.09 Mn
Mar 31, 2025 6.56 Mn
Sep 30, 2024 6.56 Mn
Sep 30, 2023 1.60 Mn